Liraglutide's Insulinogenic Effects to Be Explored Over Repeated Dosing in Healthy Volunteers
Background
Type 2 diabetes is characterized by impaired insulin secretion and sensitivity. While GLP-1 receptor agonists like liraglutide effectively improve glycemic control, their long-term impact on pancreatic beta-cell function, specifically how insulin secretion dynamics evolve with chronic exposure, remains an area of active research. Current understanding primarily focuses on acute effects, leaving a gap regarding potential adaptive or desensitization responses of beta-cells to sustained GLP-1R activation. This study aims to address this by examining changes in insulinogenic indices over repeated liraglutide administration.
Study Design
This study describes a protocol to investigate the effects of repeated liraglutide administration on insulin secretion in healthy volunteers. Participants will undergo a graded glucose infusion test (GGIT) without medication, then again 12 hours after the first dose of liraglutide, and finally after 3 weeks of treatment with liraglutide. The primary endpoint is to assess changes in insulin release and insulinogenic indices at these time points. The abstract does not specify the exact dose of liraglutide or the number of participants (n).
Results
This abstract describes a study protocol and does not present any results or findings. The research aims to investigate whether the effect of liraglutide on insulin release changes after repeated administration. Specifically, it will measure insulin secretion using graded glucose infusion tests (GGIT) at baseline, after a single dose, and after 3 weeks of treatment. The hypothesis is that the insulinogenic indices will show alterations over time, providing insights into the adaptive responses of pancreatic beta-cells to sustained GLP-1R agonism.
Key Findings
- Study aims to investigate changes in insulin release with repeated liraglutide administration.
- Hypothesis: Liraglutide's effect on insulin release may change after repeated dosing.
- Insulin release will be assessed at baseline, after 12 hours, and after 3 weeks of treatment.
Graded glucose infusion test (GGIT)is the primary method for assessing insulinogenic indices.
Why It Matters
Understanding how liraglutide's insulin-stimulating effects change over time is crucial for optimizing treatment strategies and predicting long-term efficacy. If beta-cell responses adapt or desensitize with chronic use, it could inform dosing adjustments or combination therapies. For peptide users, this research could highlight the importance of consistent dosing or potential plateaus in insulinogenic benefits. While this is a protocol in healthy volunteers, future findings could influence clinical guidelines for type 2 diabetes management, potentially leading to more personalized or adaptive treatment regimens based on the duration of GLP-1R agonist therapy.
TitrateLab articles covering Liraglutide
Written by TitrateLab, separately from the study summarized above.
